Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Synthorx, Inc.    THOR

SYNTHORX, INC.

(THOR)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Synthorx : France's Sanofi to buy biotech firm Synthorx for $2.5 billion

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/09/2019 | 05:23am EST
Sanofi CEO Paul Hudson attends the Fortune Global Forum in Paris

France's Sanofi on Monday agreed to buy California-headquartered biotechnology firm Synthorx in a cash deal worth about $2.5 billion as it steps up a push in the lucrative field of cancer drugs under its new chief executive.

Sanofi has offered to buy all the outstanding shares of Synthorx common stock for $68 per share in cash, or a 172% premium to Synthorx's closing price on Dec. 6, 2019.

"This acquisition fits perfectly with our strategy to build a portfolio of high-quality assets and to lead with innovation, as you will hear at our Capital Markets Day tomorrow, December 10," Sanofi Chief Executive Paul Hudson said in a statement.

"Additionally it is aligned with our goal to build our oncology franchise with potentially practice-changing medicines and novel combinations."

Synthorx, which posted a 2018 net loss of $56.6 million, is a clinical-stage biotech company focused on therapies for people with cancer and auto-immune disorders, according to the company's website.

HIGH PRICE?

Sanofi expects to complete the acquisition in the first quarter of 2020.

By 0946 GMT, Sanofi shares were down 0.7% at 82.94 euros.

"The acquisition price is full at a 172% premium to Synthorx Dec. 6 close price and is a lot to pay for an early stage pipeline (lead drug THOR-707 is in phase 1 trial," Liberum analysts said in a note.

Sanofi is conducting a broad strategy review under Hudson, who took over as CEO on Sept. 1. He will give initial pointers on which businesses he wants to focus on at the investor day in Cambridge, Massachusetts on Dec. 10.

Hudson has indicated significant changes were underway.

"I am bringing a little sense of urgency and prioritisation. I have set a tone already that we can move a little bit faster," Hudson told reporters in October.

"I think we have the right level of resources although perhaps not always in the right place."

Sources have told Reuters Sanofi was contemplating a joint venture or an outright sale among options for its consumer healthcare unit.

In an early sign of the new strategy, Sanofi last week agreed to sell its Seprafilm unit to medical supply company Baxter International for $350 million in cash.

Sanofi also told staff its most senior strategy boss, Muzammil Mansuri, would leave, according to an internal memo seen by Reuters.

By Dominique Vidalon and Christian Lowe

Stocks mentioned in the article
ChangeLast1st jan.
SANOFI 0.99% 90.09 Real-time Quote.-0.46%
SYNTHORX, INC. 0.00% 67.99 Delayed Quote.-2.72%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SYNTHORX, INC.
01/23SYNTHORX, INC. : Completion of Acquisition or Disposition of Assets, Notice of D..
AQ
01/21SANOFI : - Hart-Scott-Rodino waiting period expires for Sanofi :'s acquisition o..
AQ
2019Tesla gets Chinese boost, Boeing’s new troubles, scandal for Tesco…
2019WeissLaw LLP Investigates Synthorx, Inc.
PR
2019Monteverde & Associates PC Announces an Investigation of SYNTHORX, INC. - THO..
PR
2019SANOFI : to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Bi..
AQ
2019Sanofi shares rally on new margin goals, narrower drug focus
RE
2019Regeneron Shares Fall Premarket as Sanofi Signals Possible Stake Sale
DJ
2019Sanofi to Get Out of Diabetes Research -- WSJ
DJ
2019Merck, Sanofi Push To Add Cancer Drugs -- WSJ
DJ
More news
Financials (USD)
Sales 2019 -
EBIT 2019 -53,3 M
Net income 2019 -49,2 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -44,1x
P/E ratio 2020 -31,1x
Capi. / Sales2019 infx
Capi. / Sales2020 infx
Capitalization 2 175 M
Chart SYNTHORX, INC.
Duration : Period :
Synthorx, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYNTHORX, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 68,00  $
Last Close Price 67,99  $
Spread / Highest target 0,01%
Spread / Average Target 0,01%
Spread / Lowest Target 0,01%
EPS Revisions
Managers
NameTitle
Laura K. Shawver President, Chief Executive Officer & Director
Pratik Shah Chairman
Tighe M. Reardon CFO & Principal Accounting Officer
Marcos Milla Chief Scientific Officer
Joseph Leveque Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SYNTHORX, INC.-2.72%2 175
IQVIA HOLDINGS INC.4.14%31 223
LONZA GROUP12.63%30 465
CELLTRION, INC.--.--%20 042
SEATTLE GENETICS, INC.0.95%19 769
INCYTE CORPORATION-10.40%16 853